Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Vibha Ravi
Zydus Cadila Strides Ahead With NASH Filing In India
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
Granules May Be Next Private Equity Target
A recent focus on high-margin generic formulations, strong contract manufacturing business, and expected cash inflow from stake sales in joint ventures could make Granules India an attractive buy for private equity funds.
Cipla Rationalizes Sri Lanka Operations
Looking to rationalize its Sri Lankan operations, Cipla buys 40% stake held by joint venture partner Citihealth Imports in Cipla Pharma Lanka. Wholly-owned subsidiary Breathe Free Sri Lanka will be its vehicle for growth in the country.
Granules India Next On PE Buy List?
A recent focus on high-margin generic formulations, strong contract manufacturing business, and expected cash inflow from stake sales in joint ventures could make Granules India an attractive buy for PE funds.
Asia Deal Watch: Fujifilm Affiliate Out-Licenses Antifungal Candidate To Canada’s Appili
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Lupin-Aptar Launch India’s First Smart Device For MDIs At $22 Apiece
As the Indian pharma industry catches up with digitization, Lupin partners with Aptar to launch a smart device for MDIs. While there is a need for the product, whether it will find favor in a price-sensitive market remains to be seen.